Funding to accelerate the iteration of the proprietary AI-driven

用于加速专有AI驱动迭代的资金

ExCEED

超越

platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy.

平台并推进差异化产品管线的全球临床开发，包括第二代Menin抑制剂和一种新型眼科疗法。

CHENGDU, China

中国成都

,

，

Aug. 12, 2026

2026年8月12日

/PRNewswire/ --

/美通社/ --

Beyang Therapeutics Co., Ltd.

贝阳药业有限公司

('Beyang'), an AI-driven innovative drug R&D company dedicated to building a 'DreamWorks' for innovative drug discovery, today announced the successful closing of an oversubscribed Series A financing round, raising nearly $30 million.

贝漾（Beyang），一家由人工智能驱动的创新药物研发公司，致力于构建创新药物发现的“梦工厂”，今日宣布成功完成超额认购的A轮融资，募集近3000万美元。

The round was co-led by

本轮融资由……联合领投

Legend Capital

联想创投

and

和

Shanghai Healthcare Capital

上海医疗资本

, with participation from China Medical System Holdings Limited ('CMS'), Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital, and Harbor & Canton Capital. Existing investors Root Venture Partners and YuanBio Venture Capital also continued to support this round.

，并由中国医药系统控股有限公司（“CMS”）、丰磊资本、上海科技创新中心资本以及Harbor & Canton Capital参与投资。现有投资方Root Venture Partners和元生创投也继续支持本轮融资。

The proceeds will be primarily utilized to accelerate the technological iteration of Beyang's core AI + Molecular Design and Optimization platform (

所得款项将主要用于加速贝扬核心“AI+分子设计与优化”平台的技术迭代（

ExCEED

超越

), advance key pipeline candidates through clinical and pre-clinical development, and further expand its international R&D and business development teams.

），推进关键管线候选药物的临床及临床前开发，并进一步扩大其国际研发和业务拓展团队。

Validated AI Platform Driving Differentiated Innovation

经验证的AI平台驱动差异化创新

Founded in 2021, Beyang Therapeutics is led by a team with over two decades of experience in both drug discovery and computational simulation. The company has successfully established the

贝扬药业成立于2021年，由一支在药物发现和计算模拟领域拥有二十多年经验的团队领导。该公司已成功建立

ExCEED

ExCEED

platform, which integrates proprietary databases with AI and computational simulation technologies across molecular design, druggability optimization, and biological evaluation. The platform's precision and stability were recently validated internationally, ranking 8th globally among over 350 participants in the OpenADMET blind prediction challenge..

该平台将专有数据库与人工智能及计算模拟技术相整合，覆盖分子设计、成药性优化和生物评价等环节。该平台的精确性和稳定性近期在国际上得到验证，在开放ADMET盲测挑战赛中，于全球350多个参赛团队中排名第8位。

The

这

ExCEED

超越

platform empowers Beyang to

平台赋能 Beyang

generate entirely novel scaffolds

生成全新的骨架结构

—not merely variations on existing cores—enabling it to break through structural homogeneity and secure meaningful differentiation in clinical and pre-clinical studies.

——而不仅仅是对现有核心的简单变体——使其能够突破结构同质性，在临床和临床前研究中实现有意义的差异化。

Pipeline Highlights: Addressing Unmet Clinical Needs with Differentiated Advantages

研发管线亮点：以差异化优势满足未竟的临床需求

BT01001: Pioneering Non-Invasive Drug Delivery for Fundus Oculi Diseases.

BT01001：开创眼底疾病无创给药新纪元。

BT01001 is a small-molecule eye drop designed to treat retinal diseases. In pre-clinical head-to-head studies, it demonstrated best-in-class exposure in ocular tissues, with efficacy comparable to intravitreal injections of Aflibercept. The project has successfully completed Phase I SAD and MAD studies, showing excellent safety and tolerability in healthy subjects.

BT01001 是一款旨在治疗视网膜疾病的小分子滴眼液。在临床前头对头研究中，它在眼部组织中展现出同类最佳的暴露水平，其疗效与玻璃体内注射阿柏西普相当。该项目已顺利完成 I 期单次递增剂量（SAD）和多次递增剂量（MAD）研究，在健康受试者中显示出优异的安全性和耐受性。

Beyang is now advancing toward First-in-Patient trials, aiming to offer a safer, non-invasive alternative for ocular fundus diseases..

Beyang 目前正在推进首次人体临床试验，旨在为眼底疾病提供一种更安全、非侵入性的替代治疗方案。

BT01002

BT01002

: First-in-Class Second-Generation Menin Inhibitor to Overcome Resistance.

同类首创的第二代Menin抑制剂，用于克服耐药性。

BT01002

BT01002

is

是

a

一个

second-generation Menin inhibitor for KMT2Ar or NPM1 mutated acute leukemia. While first-generation inhibitors often face acquired resistance mutations, BT01002's innovative molecular design successfully overcomes all known resistance mechanisms. Currently undergoing IND-enabling studies, the project is advancing at a globally leading pace..

用于KMT2A重排或NPM1突变急性白血病的第二代Menin抑制剂。尽管第一代抑制剂常面临获得性耐药突变的问题，BT01002凭借其创新的分子设计成功克服了所有已知的耐药机制。目前，该项目正在进行新药临床试验申请（IND）所需的 enabling 研究，进展速度处于全球领先地位。

'We are grateful for the strong recognition from our Series A investors. The oversubscribed financing validates the value of our

我们感谢A轮投资者给予的高度认可。此次超额认购的融资验证了我们的价值

ExCEED

ExCEED

platform and our differentiated pipeline, 'said

平台以及我们差异化的研发管线，”表示

Qiyue Hu, Founder of Beyang

胡七月，贝阳创始人

. 'As our platform continues to deliver Best-in-Class potential, we are not only accelerating our proprietary pipeline but also actively seeking external collaborations to deliver high-value innovative drugs to patients and partners worldwide.'

“随着我们的平台持续展现行业领先的潜力，我们不仅在加速推进自主研发管线，还在积极寻求外部合作，旨在为全球患者和合作伙伴提供高价值的创新药物。”

'We observe that AI Drug Discovery (AIDD) is entering a 2.0 era characterized by vertical integration. Beyang's team combines deep industry experience with computational expertise, establishing a distinct moat with the

我们观察到，人工智能药物研发（AIDD）正进入一个以垂直整合为特征的2.0时代。贝扬团队将深厚的行业经验与计算专业知识相结合，构筑了独特的竞争壁垒

ExCEED

超越

platform, 'said

平台，”说

Fei Qi, Executive Director at Legend Capital

联想控股执行董事费奇

. 'The platform's ability to cover the full value chain—from de novo scaffold discovery to biological optimization—has been verified by experimental data, proving its capacity to continuously incubate high-potential candidates. '

“该平台覆盖从全新骨架发现到生物优化的完整价值链的能力，已通过实验数据验证，证明其能够持续孵化高潜力候选分子。”

Qiushan Guo, President of Shanghai Healthcare Capital

郭秋山，上海医疗资本总裁

, added, 'Beyang has generated highly differentiated molecules across multiple disease areas. We are particularly impressed by their next-generation Menin inhibitor, which addresses resistance issues through novel scaffold design, and their ophthalmic delivery platform that overcomes the limitations of invasive administration.

，并补充道：“Beyang 已在多个疾病领域生成了高度差异化的分子。我们对其新一代 Menin 抑制剂印象尤为深刻，该抑制剂通过新颖的骨架设计解决了耐药性问题；此外，其眼科递送平台也克服了侵入性给药的局限性。”

We look forward to seeing Beyang leverage its platform strength to produce assets with strong global competitiveness.'.

我们期待看到贝扬利用其平台优势，打造具有强大全球竞争力的资产。

About Beyang Therapeutics

关于贝扬治疗公司

Beyang Therapeutics is an AI-driven innovative drug R&D company, aiming to become the 'DreamWorks' in the field of innovative Drug Discovery. The company focuses on the development of drugs with clear mechanisms of action (MOA) and high potential for clinical translation, in the areas with unmet medical needs.

贝扬制药是一家由人工智能驱动的创新药物研发公司，旨在成为创新药物发现领域的“梦工厂”。公司专注于在存在未满足医疗需求的领域，开发作用机制（MOA）明确且具有高度临床转化潜力的药物。

Based on its proprietary .

基于其专有的。

ExCEED

超越

platform (molecular design, druggability assessment, and biological research), Beyang boasts industry-leading preclinical pipeline conversion rates. The core team comprises experienced scientists from leading pharmaceutical companies such as Pfizer, Merck, and Hengrui. They have participated in the R&D of three globally-launched small molecule drugs and successfully advanced over 10 projects into clinical trials.

凭借在分子设计、成药性评估和生物学研究方面的平台优势，贝扬拥有行业领先的临床前管线转化率。核心团队成员包括来自辉瑞、默克和恒瑞等领先制药公司的资深科学家。他们曾参与三款全球上市小分子药物的研发，并成功推动十余个项目进入临床试验阶段。

With strict target selection standards and an 'AI + experience-driven' model, the company is actively deploying in high-potential fields, accelerating the development of effective drugs to address unmet patient needs while maximizing commercial value. For more information, please visit .

凭借严格的目标筛选标准和“AI+经验驱动”模式，公司正积极布局高潜力领域，加速开发有效药物，以满足尚未被满足的患者需求，同时最大化商业价值。欲了解更多信息，请访问。

www.beyangtx.com

www.beyangtx.com

.

。

About Legend Capital

关于联想控股

Founded in 2001, Legend Capital is a leading early-stage and growth equity investor in China. With a strong focus on healthcare, it has backed numerous industry leaders, including Pharmaron, WuXi AppTec, WuXi Biologics, and Innovent Biologics.

联想之星成立于2001年，是中国领先的早期和成长期股权投资机构。公司重点关注医疗健康领域，已支持众多行业领军企业，包括康龙化成、药明康德、药明生物和信达生物。

About Shanghai Healthcare Capital

关于上海医疗资本

Shanghai Healthcare Capital is a specialized investment management platform under Shanghai Industrial Capital, managing a multi-currency, full-lifecycle fund matrix in the biomedical sector to support the innovation and development of the global biopharmaceutical industry.

上海医疗资本是上海工业资本旗下的专业投资管理平台，管理着生物医药领域的多币种、全生命周期基金矩阵，以支持全球生物制药行业的创新与发展。

Contact:

联系方式：

Minghui Tong, PhD

童明辉，博士

Beyang Therapeutics

贝阳治疗公司

[email protected]

[email protected]

+86-13265738517

+86-13265738517

SOURCE Beyang Therapeutics Co., Ltd.

来源：贝阳治疗有限公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示